Elos Medtech adjusts dividend policy and proposes no dividend for 2022
The board of directors of Elos Medtech AB has decided to update the company's dividend policy, in order to adapt the dividend to the company's large investment needs.
The new dividend policy reads:
Elos Medtech’s dividend policy stipulates that the dividend is to be based on the Group’s earnings performance, while taking into account its future development potential and financial position. The board's assessment is that any surplus funds in the coming years will need to be reinvested into the business, to cover the company's investment needs.
In line with the new dividend policy, the board of directors of Elos Medtech proposes that no dividend be paid for 2022.
Gothenburg, February 1st, 2023
Elos Medtech AB (publ)
For further information, please contact:
Stefano Alfonsi, President and CEO, +44 772 04 98 342, e-mail: stefano.alfonsi@elosmedtech.com
For additional information about the Elos Medtech Group, visit www.elosmedtech.com
This disclosure contains information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on February 1st, 2023, at 18:00 (CET).
Tags: